Skip to main content

Table 1 Lifetime attributable risk for DI-3DCRT and DI-VMAT relative to a free-breathing 3DCRT for INRT treatments with 30 Gy prescribed dose

From: Radiation-induced second malignancies after involved-node radiotherapy with deep-inspiration breath-hold technique for early stage Hodgkin Lymphoma: a dosimetric study

Cancer site Mediastinal-both Mediastinal-both & Supra-both Mediastinal-both & Supra-left Mediastinal-left
Breast     
3DCRT 0.86 0.84 0.85 0.91
VMAT 2.05 1.82 1.89 1.93
Lung     
3DCRT 0.76 0.80 0.78 0.74
VMAT 1.29 1.11 1.17 1.55
Esophagus     
3DCRT 0.94 0.98 1.06 0.90
VMAT 1.01 1.12 1.15 1.00
Stomach     
3DCRT 0.92 0.91 0.92 0.93
VMAT 0.93 0.93 0.93 0.92
Thyroid     
3DCRT 0.89 0.61 0.62 0.93
VMAT 0.88 0.67 0.79 0.93
Bone sarcoma     
3DCRT 0.88 0.87 0.82 0.88
VMAT 0.62 0.58 0.60 0.63
Soft tissue sarcoma     
3DCRT 0.89 0.83 0.83 0.90
VMAT 0.75 0.65 0.69 0.78
All cancers     
3DCRT 0.82 0.82 0.82 0.86
VMAT 1.59 1.36 1.43 1.63